The company had previously halted shipments to certain older patients following the deaths of two teenagers treated with the ...

The drop comes the day after the drugmaker said it would add a so-called black-box warning to its gene therapy Elevidys after ...

The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, ...

Sarepta Therapeutics (SRPT) stock falls as the FDA reviews if the company's gene therapy Elevidys should remain on the market following patient deaths. Read more here.

Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy appeared at risk.

Sarepta Therapeutics was approached for comment by Clinical Trials Arena but did not respond before publication. This comes ...

The U.S. Food and Drug Administration will request Sarepta Therapeutics to voluntarily stop all shipments of its gene therapy ...

Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene ...

The death will likely further stoke safety concerns around Sarepta's gene therapies, as well as raise questions around the ...

A third patient has died from acute liver failure after receiving a gene therapy treatment from Sarepta Therapeutics, the biotech company confirmed to Bloomberg on July 18. The patient died while ...

According to multiple reports, a 51-year-old man with limb-girdle muscular dystrophy died from acute liver failure after ...

Shares of Sarepta Therapeutics declined 20% in early trading on Friday after media reports that a patient who had received one of its experimental gene therapies has died, deepening investor concern ...